Enterprise Value

7.513B

Cash

614.8M

Avg Qtr Burn

-103.6M

Short % of Float

12.93%

Insider Ownership

0.57%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Aficamten (CK-274) (cardiac myosin inhibitor) Details
Heart disease, Hypertrophic cardiomyopathies

NDA

Submission

Omecamtiv Mecarbil (cardiac myosin activator) Details
Pancreatic cancer, Heart disease, Heart failure

NDA

FDA meeting

CK-3828136(CK-136) (cardiac troponin activator) Details
Heart failure, Heart disease, Epilepsy

Phase 1

Data readout

Phase 1

Data readout

Failed

Discontinued